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Key Points  
 N-glycosylation sites are acquired early in disease and persist during tumour progression 
despite therapy. 
 Scarcity of N-glycosylation sites-negative subclones and their loss during progression suggest 
positive clones expand preferentially. 
 
Abstract  
Follicular lymphoma B cells undergo continuous somatic hypermutation (SHM) of their 
immunoglobulin variable region genes, generating a heterogeneous tumour population. SHM 
introduces DNA sequences encoding N-glycosylation sites Asparagine-X-Serine/Threonine (N-gly sites) 
within the V-region that are rarely found in normal B cell counterparts. Unique attached 
oligomannoses activate B cell receptor signalling pathways following engagement with calcium-
dependent lectins expressed by tissue macrophages. This novel interaction appears critical for tumour 
growth and survival. To elucidate the significance of N-gly site presence and loss during ongoing SHM, 
we tracked site behaviour during tumour evolution and progression in a diverse group of patients 
through next-generation sequencing. A hierarchy of subclones was visualised through lineage trees 
based on SHM semblance between subclones and their discordance from the germline sequence. We 
observed conservation of N-gly sites in >96% of subclone populations within and across diagnostic, 
progression and transformation events. Rare N-gly-negative subclones were lost or negligible from 
successive events in contrast to N-gly-positive subclones which could additionally migrate between 
anatomical sites. Ongoing SHM of the N-gly sites resulted in subclones with different amino acid 
compositions across disease events, yet the vast majority of resulting DNA sequences still encoded for 
an N-gly site. The selection and expansion of only N-gly-positive subclones is evidence of the tumour 
cells dependence on sites despite the changing genomic complexity as the disease progresses. N-gly 
sites were gained in the earliest identified lymphoma cells, indicating they are an early and stable 
















Follicular lymphoma (FL) is a biologically and clinically heterogeneous disease that remains incurable. 
Although the majority of patients follow an indolent course, a high-risk group are prone to early 
progression or transformation to aggressive lymphoma associated with a dismal prognosis. For these 
patients, current therapies are suboptimal and uncovering changes occurring early during disease 
development is essential to improving prognosis. 
Despite the loss of one immunoglobulin allele through the t14;18 translocation 1 and ongoing somatic 
hypermutation (SHM) of the immunoglobulin heavy-chain variable region gene (IGHV) that can 
introduce crippling IGV mutations, all detectable tumour subclones retain functional expression of the 
surface immunoglobulin throughout disease, resulting in thousands of tumour subclones displaying 
distinct but clonally related IGHV sequences. This retention suggests a tumour dependence on 
signalling through the B cell receptor (BCR). Through SHM, replacement mutations introduce amino 
acid sequence motifs consisting of Asparagine (N)-X-Serine/Threonine (S/T), where X can be any amino 
acid except proline. 2-4 These sequences are known as N-glycosylation (N-gly) sites and are found in 
>90% of FL cases. 5, 6 N-gly sites are rarely found in normal B cells, 7 indicative of a pathogenic function. 
Unusual glycans terminating with high-mannose attach to sites and activate BCR signalling pathways 
following engagement with lectins. 8-12 This novel interaction represents a critical mechanism by which 
tumour cells survive in the germinal centre (GC), accumulating mutations of epigenetic modifiers early 
during FL pathogenesis. 13, 14 
The behaviour of N-gly sites during disease evolution and progression has been investigated by IGHV 
cloning technique in a number of FL cases 5 and in one case of contiguous FL and in situ follicular 
neoplasia (ISFN). 15 These studies have indicated conservation of acquired N-gly sites within identified 
clones. However, clone numbers were limited in these studies, underrepresenting the extent of 
intraclonal diversity. Furthermore, as analysis has been restricted to a single disease event, behaviour 
of N-gly sites over time has not been addressed and would be critical in determining their role in 
disease initiation and progression. To address this requires comprehensive IGV analysis of the clonal 
repertoire taken from subsequent (temporal) biopsies, ranging from a relatively early time point in 
disease manifestation (e.g. diagnosis) to a time point at which the disease has become genetically and 
clinically distinct (e.g. relapse and transformation). As SHM continues during disease progression and 
transformation, the stepwise process can be visualised through lineage trees rooted to a putative non-
malignant germline IGV sequence, making them an important tool in B cell evolutionary studies.  
Our goal was to investigate the behaviour of N-gly sites during the disease course. We analysed the 
incidence and maintenance of sites within the tumour clones of six patients taken at different time 
points of disease. This included analysis of events from different anatomical sites. This is the first study 
that has analysed the relationship between FL progression and N-gly sites in patients who have 
undergone different lines of therapy and presented with different clinical courses, reflecting the 
heterogeneous nature of the disease.  
We found that N-gly sites are acquired within early FL clones and are retained in the intraclonal 
population despite ongoing SHM. A striking observation is that sites are a universal determinant of 
both cell expansion and cell fate, as evidenced by the low frequency of N-gly site-negative subclones 
in and across diagnostic, progression and transformation events and their disappearance in 







Three individuals with FL were selected on the availability of genomic DNA derived from sequential 
tumour lymph node biopsies that had previously undergone somatic variant profiling to reveal a 
‘sparse’ or ‘rich’ disease evolution pattern based on degree of genetic semblance. 13 Patient’s 1 and 3 
were categorised as ‘sparse’ and patient 2 categorised as ‘rich’. Samples were selected based on 
detection of a clonal IGHV (IGHVDJ) rearrangement through Sanger sequencing (Supplemental 
Methods). In total, 8 samples were selected, all carrying an IgH-VH3 rearranged major tumour clone 
(major clone). All samples were obtained after written informed consent in accordance with the 
Declaration of Helsinki and the London Research Ethics Committee. ~50ng of IGHV genomic DNA 
amplicons prepared using JH consensus and VH3-FR1 primers were sent for 2x250bp paired end 
sequencing using the Miseq Illumina platform (Genewiz, NJ). As primers bind within the FR1 and JH 
regions, a portion of these regions were absent from the sequencing data. The sequential steps 
involved in the analysis of Illumina reads and identification of tumour related subclones are detailed 
in the Supplemental Methods. Additional tumour related reads covering the IGHV gene for 2 patients 
over different disease events were available from our collaborator (patients 4 and 5) and were 
produced using Roche 454 Life Sciences Genome Sequencer FLX. 16 Additional raw IGHV data files 
produced from the MiSeq platform were obtained from the NCBI database (BioProject PRJNA240336) 
for patient 6. 17 Clones were analysed for acquired N-gly sites using the NetN-glyc 1.0 server. Lineage 
trees based on the SHM profiles of clones were generated using IgTree, 18 detailed in the Supplemental 
Methods.  
Statistical analyses 
Two-way ANOVA was performed using GraphPad Prism (GraphPad Software, La Jolla, CA). 
Results  
High throughput sequencing analysis of tumour related subclones 
Sequencing metrics for patients 1-3 are found in Supplemental Table 1. We generated 0.81 to 1.17 
million paired-end reads/sample (average 1.09 million) (Supplemental Table 2). In total, we identified 
0.12 to 0.46 million (average 0.29 million) VDJ junctions per sample. The major clone was identified as 
being the dominant VDJ rearrangement in the sample (Table 1) and tumour related reads were 
identified as described in the Supplemental Methods. The number of unique subclones that reads 
encoded for is detailed in Table 1. To ensure detection of all tumour subclones in the different samples 
we utilized VH3 family oligonucleotides in the single sequencing run rather than tumour specific 
primers. Therefore, contaminating sequences from normal B cells were observed for each sample and 
the number of unique VDJ rearrangements/sample are stated in in Table 1. Patients 4-6 sequencing 
data in Table 1 was extracted from the original articles. 16, 17 The relatively greater number of unique 
VDJ rearrangements detected for patient 6 is due to the sequencing approach amplifying all VH 
families. 17 There is a heterogeneous level of contaminating B cells, as indicated by the percentage of 
merged reads expressing the dominant tumour rearrangement, ranging from 53.3% to 99.03% (Table 
1 and Supplemental Table 2).   
Site conservation is a universal feature of the tumour clonal population 
We sequenced the IGHV gene in samples obtained at sequential time-points of FL in six patients and 
interrogated the derived tumour sequence for the acquisition of N-gly sites. Details regarding patient 
samples can be found in Supplemental Table 3. All major clones identified across samples contained 
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one or more N-gly sites (Table 2). With the exception of patient 5, N-gly sites were conserved across 
disease events, despite patients undergoing several lines of therapy in between biopsies 
(Supplemental Table 3). For patient 1 and the 4th N-gly site of patient 2, sites were conserved in 
transformation events through non-silent mutations that impacted the amino acid sequence (e.g. 
NFS>NVS). For the remaining sites in patient 2 and sites in patient 3 and 4, the amino acid sequences 
were conserved across disease events. Conservation of sites is also supported in our extension cohort 
of serial FL and transformed samples from patients A-E that underwent IGHV Sanger sequencing 
(Supplemental Table 4). Patient 5 and 6 sequential samples were derived from different anatomical 
sites (Supplemental Table 3). For patient 5, the two disease events have distinct N-gly sites; NFS in the 
CDR1 region (1st relapse event) and NLT in the FR3 region (3rd relapse event). For patient 6, all events 
contain the same N-gly site and amino acid motif (NGS) (Table 2). To elucidate whether N-gly site 
acquisition is a clonal event, we interrogated the subclone population by next-generation sequencing. 
For patients containing one N-gly site in their major clone, ≥97% of the subclone population within 
and across disease events maintained the site (Table 2). For patients 2 and 4, which had multiple N-
gly sites, no subclone with the complete absence of N-gly sites was detected. For patient 2, the 1st, 2nd 
and 3rd sites were conserved in >96% of subclones across events. The 4th site was conserved in 97.2% 
of clones in the 1st relapse sample and in 82% and 85% of subclones in the 3rd relapse and 
transformation samples, respectively. Interestingly, for all patients no further N-gly site accumulated 
within or across events that were not found in the major clone. This infers that site acquisition is a 
conserved event. 
SHM diversity within the N-glycosylation site indicates a selective retention of site-positive 
subclones 
Table 3 highlights the number of unique subclones that have a different sequence in the N-gly site 
region compared to the major clone of the disease event. As the N-gly site is encoded by nine 
nucleotides, these subclones differ from the major clone by at least one nucleotide within the N-gly 
site region. There is wide variation in percentage of affected subclones between patients, ranging from 
0 to 58.41% of the total subclone population, indicating the (largely) random targeting of SHM within 
the variable region. For patients 1, 2 (sites 1-3), 3, 4 (site 1) and 5, the majority of affected subclones 
across disease events maintain the N-gly site, indicating a positive selection (Figure 1a). Analysis of the 
codon sequences of these positive subclones across patients and events revealed that N-gly sites are 
retained through either synonymous mutations or non-synonymous mutations. The profiling of these 
subclones from patient 3 is used to highlight these two means of N-gly site retention in Figure 1b.  
For patient 2, the 4th N-gly site was absent in the majority of affected subclones in the 3rd relapse and 
transformation events, yet remaining N-gly sites may be supporting their survival and expansion as 
indicated by their high percentage in the subclone population. While in patient 6 the affected 
subclones in the first two events were mostly N-gly site positive, the affected subclones of the relapsed 
tFL event were predominantly site negative. As this is a relatively late disease event compared to the 
other patients, the N-gly site may have become redundant in promoting tumour survival. However, it 
is important to point out that these negative subclones make up 2.7% of the total subclone population 
(Table 3). Furthermore, site-negative subclones only making up ≤1% of the total count number in 
samples expressing only one N-gly site (Supplemental Table 5), indicating they are a minor component 
of the tumour bulk. 
N-glycosylation sites in distinct anatomical sites 
The distinct anatomical sites for patients 5 and 6 serial samples make them important in studies 
regarding the genealogy of N-gly sites. For both patients, serial disease events were derived from the 
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same precursor B cell, as evidenced by a shared VDJ rearrangement and t(14;18) translocation. For 
patient 5, the two events have distinct N-gly sites (Table 2) whereas for patient 6, all events contain 
the same N-gly site and amino acid motif (NGS). When comparing the subclones of patient 5, we 
observe a clear discordance in the SHM pattern of the two temporal populations and how this 
translates into a highly distinct amino acid sequence (Supplemental Figure 1). This suggests that for 
patient 5, there was early divergence of the precursor tumour cell before N-gly site acquirement 
whereas for patient 6, the precursor cell diverged after acquiring the N-gly site (Figure 2). Patient 5 
demonstrates that N-gly acquirement may not be an event of an early divergence evolution model, 
instead occurring in anatomical site-specific ancestral cells that have undergone unique SHM 
processes. However, acquirement occurs early in these site-specific cells, as illustrated by the 
presence of N-gly sites in 97.14% and 99.19% of unique subclones in the 1st and 3rd relapse events, 
respectively (Table 2). 
N-glycosylation site positive subclones are important in disease progression and migration between 
anatomical sites. 
As described above and with the exception of patient 5, N-gly sites are conserved in the clonal 
population across disease events. When we compared subclone populations, the majority of 
subclones for each disease event are unique, highlighting the inter-tumour heterogeneity generated 
through SHM (Figure 3). The number of shared subclones make up 0.03-27.5% of the total tumour 
subclones identified across disease events. These subclones survive for years, as indicated by the 
intervals between temporal biopsy acquirement (Supplemental Table 3).  
Analysis of shared subclones revealed they are all N-gly site-positive. Patient 3 was an exception as 
1.5% of the shared clones were negative (n=20). Interestingly, most of these negative clones make up 
a higher percentage of the total tumour count in the successive disease event, suggesting that they 
confer an advantage (Supplemental Table 6). The lack of shared N-gly site-negative subclones in all 
other patients indicates that progression subclones are dependent on N-gly sites for their long-term 
survival.  Analysis of shared subclones in patients 1 and 2, in which the amino acid composition of N-
gly sites changes between disease events in both the major clones and subclone populations (Table 
2), reveals that subclones giving rise to transformation tumours were already pre-existent as minor 
subclones in earlier events, gaining clonal dominance following therapy to generate the 
transformation tumours. This subclone plasticity relies on the conservation of N-gly sites, indicating 
the important role sites provide subclones involved in disease progression. 
Subclones were also shared between biopsy sites, making up 0.4% and 0.3% of the overall subclone 
population across all disease events for patients 5 and 6, respectively. Similar to the other patients, 
shared subclones of both patients were all N-gly site positive, with patient 5 subclones containing the 
site of the first event (NFS motif in the CDR2 region). This indicates that migratory subclones require 
site presence and could represent a tumour cell feature which is critical for establishing disease in new 
locations, however this requires investigation in a larger cohort. The lack of shared subclones 
containing the N-gly site of the second disease event in patient 5 indicates that this disease event did 
not arise due to a pre-existing minor subclone in the first event gaining clonal dominance and 
repopulating the tumour at another site. This is in contrast to the subclone plasticity we observe in 
patients 1 and 2, described above. 
N-glycosylation sites are acquired early in disease evolution 
We can gain insight into tumour evolution by analysing the degree of SHM in each subclone. The range 
of SHM for each patient is indicated in Table 4, in which the least and most mutated subclones for 
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each disease event (compared to their germline sequence) were identified by the IMGT High V-QUEST 
program. The % difference in homology between the least and most mutated subclones ranged from 
2.0 to 21.7%.   
For patients 1, 4 and 6, N-gly sites were acquired within their least mutated subclones in all their 
disease events. For patient 6, acquirement of the CDR3 located site was observed after only four 
nucleotide substitutions (97.8% sequence homology to germline V gene) (Table 4).  However, for the 
least mutated subclone of the transformed event for patient 3, the N-gly site isn’t acquired despite 
the subclone harbouring a relatively greater number of point mutations. Despite this heterogeneity, 
N-gly sites are conserved once acquired despite ongoing SHM, as evidenced in the most mutated 
subclones of all patients. Therefore, subclone selection is based on conserving N-gly sites in spite of 
active mechanisms which have the potential to disrupt this. 
Lineage trees specifically based on VDJ sequences were used to visualise the evolutionary intraclonal 
hierarchy.18 For patients 4 and 5, the complete hierarchy can be visualised in lineage trees (Figures 4 
and 5 and Supplemental Figure 2).  
For patient 4, the earliest experimentally derived subclones (identified as filled circles closest to the 
germline Ig sequence at the top of the tree) are N-gly site-positive. While patient 4 does not have any 
truly negative subclones, several subclones lose at least one N-gly site. Some of these subclones are 
observed to undergo further SHM and re-acquire the lost site (Figure 4), giving rise to several further 
clones. This is in contrast to patient 5 in which the loss of the single N-gly site results in the subclone 
not undergoing further diversification or expansion (Figure 5). One N-gly site-negative subclone in the 
1st relapse event is placed high in the tree and only differs from the germline sequence by 5 bases. 
This subclone corresponds to the least mutated subclone (98% homology) highlighted in Table 4, 
indicating this clone never acquired the N-gly site. The other site-negative subclones were 
descendants of site-positive clones because of ongoing SHM. As these clones are lost from progression 
samples, we can infer their elimination.  
N-glycosylation site-negative clones arise from further SHM of site-positive clones 
With greater numbers of N-gly site-negative subclones owing to an increase in overall subclones, 
patients 1, 3 and 6 lineage trees give a more comprehensive insight into the behaviour of site-negative 
clones in the tumour hierarchy (Figure 6). As patient 2 did not have any truly negative subclones, the 
analysis was omitted. However, these negative subclones represent a minority within the 
heterogeneous population. For patient 1, negative clones represented 1.7% and 1.8% of the subclone 
population in diagnosis and transformation events, respectively. For patient 3, negative clones found 
in 2nd relapse, 3rd relapse and transformation represented 2.5%, 2.1% and 1.8% of the population, 
respectively. For patient 6, negative clones represent 1.6%, 2.1% and 2.7% of the subclone population 
in FL diagnosis, tFL diagnosis and tFL relapse events. N-gly site-negative clones were found to arise 
from either a positive or a negative clone, through a single nucleotide variant. Several negative clones 
can arise from a shared positive ancestor, as depicted through the wide branching. Further SHM in 
these negative clones does not result in site re-acquirement or gain of new sites.  
Discussion 
The high propensity of relapse in FL patients suggests that current therapies are not successfully 
targeting the early aberrations needed to propagate disease, leading to acquirement of further 
mutations that reduce effective treatment options. Therefore, uncovering and targeting features of 
FL ancestral cells may offer durable outcomes for patients. 
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We report for the first time the behaviour of N-gly sites during disease progression by analysing the 
clonal repertoire of temporal FL samples based on IGHV sequencing. Samples ranged from diagnosis 
to transformation and included a mixed patient cohort with variable clinical disease courses, reflecting 
the heterogeneous nature of the disease (Supplemental Table 3). All patients harboured at least one 
acquired site in their earliest disease event that was conserved in both the heterogeneous subclonal 
population and the overall tumour mass. N-gly sites were also retained in sequential relapse and 
transformation samples although for patients 1 and 2, sites were conserved through non-synonymous 
mutations (Table 2). Analysis of the nine base pair region encoding the N-gly site for each patient 
revealed a group of subclones harbouring a different nucleotide sequence in the site to that of the 
major clone, due to ongoing SHM. However, the majority of these affected subclones maintained the 
N-gly site for patients 1, 2 (sites 1-3), 3, 4 (site 1) and 5 across disease events through synonymous 
and non-synonymous mutations (Figure 1a). Although the acquirement of additional ‘driver’ 
mutations through natural or therapy-related selection pressures may dampen the tumour’s 
microenvironment dependency at later stages of disease, the conservation of N-gly sites suggest they 
retain an important functional significance.    
The presence of negative subclones is an expected occurrence, as SHM does not differentiate between 
seemingly favourable and non-favourable mutations. Lineage trees have revealed how negative clones 
are derived from positive clones, suggesting acquirement of sites is an early event. As these negative 
clones represent only a small % of the tumour population, they are likely to be outcompeted by N-gly 
site-positive clones perhaps due to loss of the microenvironmental interaction provided via the added 
mannoses. Negative clones can still undergo SHM but do not reacquire sites in their progeny and, with 
the exception of Patient 3, are lost from subsequent samples, indicating that they are not selected to 
undergo expansion or long-term survival. Sanger sequencing of the light chain variable region for 
patient 3 did not reveal additional N-gly sites in the major clone. However, while we cannot assume 
that sites in the light chain are not acquired subclonally and may therefore be present in the negative 
subclones of patient 3, determining the light chain N-gly site status of IGHV-based subclones is 
currently impossible. 
Patient 5 provided an interesting case for two reasons; the different anatomical sites for the two 
events and the discordant SHM within the IGHV between the two clonal populations. This discordance 
suggests an early divergence, where an ancestral cell with limited SHM, migrated from one site to 
another where selection pressures drove the outward growth of subclones with a specific SHM 
pattern. However despite IGHV sequence heterogeneity, the acquirement of N-gly sites within each 
population at different locations illustrates that sites are an essential feature of FL. The sharing of two 
subclones with the N-gly site of the diagnostic sample highlights the trafficking ability of site-positive 
subclones between anatomical sites, which is also observed in patient 6 (Figure 3). However for 
patient 6, SHM patterns between events were highly similar and the CDR3 N-gly site was conserved 
throughout, suggesting a late divergency between events from a shared ancestral cell. Therefore, N-
gly sites are required in both early and late divergency models of evolution. 
The conservation of N-gly sites within and across disease events and the lack of accumulation during 
ongoing SHM suggests they are an early and stable event in FL pathogenesis. Early events are usually 
determined through their conservation within temporal samples and for patients 1-3, WGS/WES had 
previously identified key genetic aberrations within a putative ancestral cell, known as the common 
progenitor cell (CPC). 19-21 Patients 1 and 3 had a ‘sparse’ CPC due to the lack of shared genetic 
aberrations across temporal samples, suggesting an early divergency with episodes arising from more 
genetically independent pathways. However, despite this mutational heterogeneity between events, 
N-gly sites are conserved, identifying an important feature of the CPC. This is a significant finding as 
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the CPC is believed to be the reservoir pool from which successive disease events arise, accounting for 
the high relapse rates experienced by the majority of patients. The latency between biopsy sampling 
(Supplemental Table 3), suggests an N-gly site-positive CPC that is able to remain dormant for many 
years before a mutational event leads to a new disease episode. The mannose-lectin interaction 
enables tumour retention and survival of the CPC permitting the accumulation of genetic events that 
lead to overt disease, suggesting a critical priming event in FL manifestation. Although epigenetic 
deregulation is a considered CPC event as evidenced in the previous genetic profiling of patient’s 1-3 
samples, our data implies that it is not solely sufficient for ‘driving’ the disease. Instead, it seems that 
the N-gly site profile determines which clones are able to expand and survive during disease 
progression, irrespective of the genetic profile of the subclones. Analysing the genetic profile of N-gly 
site-negative subclones will determine the validity of this hypothesis. 
Although the t14:18 translocation can be found in healthy circulating B cells which do not go on to 
become malignant, 22-24 N-gly sites in the variable region are restricted to GC-derived lymphomas 3 
indicating an attractive and tumour specific therapeutic target which may lead to the loss of a critical 
CPC-microenvironmental interaction and reduce the frequency of relapse. The presence of N-gly sites 
in the presumed FL precursor, ISFN15 supports the theory of N-gly sites occurring at an early stage of 
pathogenesis, being acquired even before disease manifestation. Figure 7 summarises how N-gly sites 
impact the evolution of disease.  
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Table 1. Summary of VDJ sequencing results for patients 1-6. For patients 4 and 5, information in table was 
obtained from reference 16 and patient 6 information was obtained from reference 17. * Although samples of 
patient 5 have different DJ rearrangements according to IMGT, when aligned they show highly similar CDR3 
regions and share a t(14:18) breakpoint, indicating a clonal relationship









(% of total 
reads) 





Diagnosis V3-30, D3-16, J6  29 99.03 1690 
Transformation V3-30, D3-16, J6 
 
313 94.95 2727 
2 
1st relapse V3-11, D3-16, J1  105 95.04 3530 
3rd relapse V3-11, D3-16, J1  12 99.33 3032 
Transformation V3-11, D3-16, J1  129 99.23 3966 
3 
2nd relapse V3-48, D1-26, J4  164 88.23 4103 
3rd relapse V3-48, D1-26, J4  261 71.10 2057 
Transformation V3-48, D1-26, J4  143 84.81 1592 
4 
1st relapse V3-48, D3-10, J6  101 56.60 81 
2nd relapse V3-48, D3-10, J6  324 69.70 248 
5 
1st relapse V3-23, D4-23, J6  224 53.30 140 
3rd relapse V3-23, D3-3*, J5*  433 70.70 371 
6 
FL diagnosis V3-23, D5-18, J6  7,931 82.40 2510 
tFL diagnosis V3-23, D5-18, J6  2,436 89.60 3442 
tFL relapse V3-23, D5-18, J6  1,204 93.10 4749 
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Table 2. N-gly sites identified in the major clone of six FL patients taken at different time points of disease. Italic text in red refers to differences in the location or amino 
acid (aa) sequence of N-gly sites, referred to as N-gly motif, within the major clone across temporal samples. The major clone was determined by the highest count number. 
The multiple values in patient 2 and 4 relate to the multiple N-gly sites observed. The majority of subclones across patients and disease events retain the N-gly site of the 
major clones (P<0.0001). AA; amino acid. Numbers given under the heading ‘AA position of N-gly site’ refer to the position of the middle amino acid making up the N-gly 
site according to IMGT numeration of the variable region. 
Patient  Disease Event 
No of N-gly 
sites  
Region in IGHV 
AA position of N-gly 
site 
N-gly motif in major 
clone 
% of unique subclones with N-gly site 
of major clone present 
1 Diagnosis 1 CDR3 108 NFS 98.31 
Transformation 1 CDR3 108 NVS  98.17 
2 
1st relapse 4 CDR1, FR2, CDR2, FR3  30, 39, 56, 85 NFS, NMS, NIT, NNS 99.01, 99.01, 98.87, 97.22 
3rd relapse 4 CDR1, FR2, CDR2, FR3  30, 39, 56, 85 NFS, NMS, NIT, NNS 99.31, 96.8, 98.75, 81.83 
Transformation 4 CDR1, FR2, CDR2, FR3  30, 39, 56, 85 NFS, NMS, NIT, NNT 98.54, 98.16, 97.71, 84.95 
3 
2nd relapse 1 CDR2 56 NIS 97.47  
3rd relapse 1 CDR2 56 NIS 97.91 
Transformation 1 CDR2 56 NIS 98.18 
4 
1st relapse 2 FR2, CDR3 48, 108 NKS, NNS 97.53, 100 
2nd relapse 2 FR2, CDR3 48, 108 NKS, NNS 97.98, 99.6 
5 
1st relapse 1 CDR1 30 NFS 97.14 
3rd relapse 1 FR3 94 NLT  99.19 
6 
FL diagnosis 1 CDR3 108 NGS 98.41 
tFL diagnosis 1 CDR3 108 NGS 97.94 
tFL relapse 1 CDR3 108 NGS 96.74 
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Patient  Disease Event 
No of unique tumour 
related subclones  
No of unique tumour subclones with different 
codon sequence in N-gly site region to the MC 
(% of total subclones) 
Subclones with different codon sequence in N-gly region 
% of subclones without N-gly 
site  
% of subclones with N-gly 
site  
1 
Diagnosis 2727 107 (3.92) 1.69 2.24 
Transformation 1690 110 (6.51) 1.83 4.67 
2 
1st relapse 3530 96 (2.72), 113 (3.20), 2062 (58.41), 226 (6.40) 0.99, 0.99, 1.13,  2.78 1.73, 2.21, 57.28, 3.63 
3rd relapse 3032 145 (4.78), 239 (7.88), 982 (32.39), 737 (24.31) 0.69, 3.10, 1.25, 18.17 4.09, 4.68, 31.13, 6.13 
Transformation 3966 134 (3.38), 148 (3.73), 1370 (34.54), 747 (18.84) 1.46,  1.84, 2.29, 15.05 1.92, 1.89, 32.25, 3.78 
3 
2nd relapse 4103 385 (9.38) 2.53 6.85 
3rd relapse 2057 179 (8.70) 2.09 6.61 
Transformation 1592 455 (28.58) 1.82 26.76 
4 
1st relapse 81 28 (34.57), 0 2.47, 0 32.1, 0 
2nd relapse 248 14 (5.65), 1 (0.40) 2.02, 0.40 3.63, 0 
5 
1st relapse 140 22 (15.71) 2.86 12.86 
3rd relapse 371 21 (5.66) 0.81 4.85 
6 
FL diagnosis 2510 946 (37.69) 1.59 36.10 
tFL diagnosis 3442 265 (7.70) 2.06 5.64 
tFL relapse 4749 214 (4.51) 2.70 1.81 
Table 3. No. of unique subclones that have a different codon sequence at the location of the N-gly site to that of the major clone. The percentage of these subclones that are 









Table 4: N-gly site status in most and least diverse subclone based on degree of SHM compared to V gene germline sequence. Sequences were analysed for presence or absence 






  Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 
Least mutated subclone FL tFL FL1 FL3 tFL FL2 FL3 tFL FL1 FL2 FL1 FL3 FL tFL tFL1 
% homology to G.L V 
gene sequence  96.4 98.0 88.7 88.3 94.4 84.7 86.1 95.6 89.4 89.0 98.0 89.1 97.8 93.0 92.3 
N-gly site presence (Y/N) Y Y Y, Y, Y, Y Y, Y, Y, N N, N, N, Y Y Y N Y,Y Y, Y N Y (FL1 site) Y Y Y 
Most mutated subclone                               
% homology to G.L V 
gene sequence  84.3 83.9 84.7 84.3 84.3 79.0 79.4 79.6 87.4 86.9 87.5 81.5 79.4 71.3 73.5 
N-gly site presence (Y/N) Y Y Y, Y, Y, Y Y, Y, Y, Y Y, Y, Y, Y Y Y Y Y,Y Y,Y Y Y Y Y Y 
                                
% difference in 
homology between  
12.1 14.1 4.0 4.0 10.1 5.7 6.7 16.0 2.0 2.1 10.5 7.6 18.4 21.7 18.8 





Figure 1. Subclones with distinct codon sequences in the 9 basepair region of the N-gly site region. 
a) N-gly site status of subclones with a different codon sequence in N-gly site region to that of the 
major clone. N-gly site positive subclones represented here do not display either the same asparagine 
or serine/threonine encoding nucleotide sequence as that of the major clone. The middle codon for 
all sequences was checked to ensure for the absence of proline as this middle amino acid would 
negatively affect the functionality of the N-gly site. Percentages were calculated from the values in 
columns 5 and 6 from Table 3.   b) Patient 3 subclones from the three disease events are illustrated as 
an example. The pie charts provide an overview of the distribution of subclones harbouring either 
synonymous (green) or non-synonymous (orange) mutations compared to the sequence of the major 
clone. The numbers inside the pie charts are representative of the actual number of subclones. For 
the 2nd relapse and transformation subclones, the majority of subclones have a different amino acid 
sequence encoding for the N-gly site (non-synonymous) whereas the majority of the 3rd relapse 
subclones maintain the amino acid sequence found in the major clone, which is NIS (synonymous). 
The tables highlight the variety of amino acid sequences that encode for N-gly sites (e.g. NIT, NVT, NIS) 
found in these subclones and the diverse range of codon sequences that are responsible for both these 
synonymous and non-synonymous mutations. Numbers in brackets represent the number of unique 
subclones presenting with the particular codon sequence. 
Figure 2. Early and late divergent evolution and N-gly acquirement. a) Representative of patient 5. 
N-gly sites are acquired in site-specific precursor cells, explaining the different N-gly sites we observe 
in the 1st and 3rd relapse events taken from distinct anatomical sites (Table 2).  b) Representative of 
patient 6. Here, the N-gly site was acquired in a shared precursor cell before divergence of tumour 
populations to distinct anatomical sites. G.L is an abbreviation of germline. Letters in cells represent 
the N-gly site amino acid sequences.  
Figure 3. Venn diagrams showing the number of shared and distinct subclones across disease events. 
Diagrams were generated by comparing the VDJ sequences of subclones in each disease event of a 
patient (Table 1) to identify the number of shared and unshared subclones. The numbers in the 
overlaps represent the number of shared subclones between disease events whereas the numbers 
outside the overlap represent the number of unique subclones present for the particular disease 
event. Values in brackets represent the number of subclones as a % of the total number of subclones 
identified across all disease events. These values were rounded to 1 decimal point. For patient 3, the 
transformation sample was omitted from analysis due to the difference in CDR3 length in comparison 
to the 1st and 2nd relapse. FL-FL diagnosis, FL1-1st relapse, FL2-2nd relapse, FL3-3rd relapse, tFL1-
relapsed tFL. 
 
Figure 4. Lineage trees for patient 4 showing the N-gly site status of each subclone. The left panel 
represents the lineage tree of the 1st relapse event whereas the right panel represents part of the 
lineage tree of the 2nd relapse event. Each subclone is represented by a node, major clones are 
indicated in larger nodes. Nodes are split into two colours to represent the two N-gly sites found in 
the FR2 and CDR3 regions for patient 4 (Table 2). FR2 site is represented in left half and CDR3 site is 
represented in right half of the nodes. Nodes differing in colour to the major clone represent subclones 
with different N-gly site codon sequences. Black represents absence of the FR2 or CDR3 site. Major 
clones between the two disease events have a different codon sequence in the FR2 N-gly site, 
indicated by the difference in colour. Nodes in boxes represent shared subclones between events. 
White nodes represent subclones inferred to exist but not detected through 454 sequencing. Germline 
nodes are in grey at the top of the tree, marked G.L. Numbers on branches indicate >1 mutation 
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separating one node from the other. The full lineage tree of 2nd relapse event are provided in 
Supplemental Figure 2a. MC; major clone. 
Figure 5. Lineage trees for patient 5 showing the N-gly site status of each subclone. The left panel 
represents the lineage tree of the 1st relapse event whereas the right panel represents part of the 
lineage tree of the 3rd relapse event. Black nodes represent nodes that are absent of N-gly site found 
in the major clone. Nodes differing in colour to the major clone represent subclones with different N-
gly site codon sequences. The 4 nodes split into two colours (black and orange) in the right panel 
represent subclones which are absent for the N-gly site found in the major clone of the 3rd relapse 
(NLT) event but are positive for the N-gly site found in the 1st relapse event (NFS). Shared subclones 
are highlighted in boxes. The full lineage tree of the 3rd relapse event are provided in Supplemental 
Figure 2b. 
Figure 6. Hierarchy of N-gly site-negative clones in relation to their direct ancestral clone for Patient 
1, 3 and 6.  This diagram represents part of the lineage trees as the majority of subclones (which are 
positive) are not shown and the interconnection between clones from a germline sequence is not 
depicted. Only the negative subclones, their parent clone and their progenitor clones are depicted 
here to highlight their generation and contribution to the clonal repertoire within an event.  For all 
patients, black nodes represent N-gly site-negative clones. White nodes represent clones not detected 
by the sequencing platform but predicted to exist by the IgTree program. All white nodes are assumed 
to contain the N-gly site due to a number of other experimentally detected progeny clones being site-
positive. Grey nodes in the patient 1 diagnosis event represent N-gly site positive subclones that 
contain the same N-gly site-encoding codon sequence to the major clone. Dark red nodes in patient 1 
transformation represent N-gly site positive subclones that contain the same N-gly site-encoding 
codon sequence to the major clone of the event. Pink nodes in patient 3 represent N-gly site positive 
subclones that contain the same N-gly site-encoding codon sequence to the major clone of the event. 
Green nodes in patient 6 represent N-gly site positive subclones that contain the same N-gly site-
encoding codon sequence to the major clone of the event. Other coloured nodes in trees represent 
N-gly site-positive clones which contains a different codon sequence in the N-gly site compared to the 
major clone of the disease event. The full lineage trees can be requested from the corresponding 
author. 
Figure 7. Simplified model of FL evolution and progression based on the high throughput sequencing 
of the immunoglobulin heavy chain variable gene and N-gly analysis. Following the t14;18 
translocation during a likely error in VDJ recombination in the bone marrow, the B cell migrates to the 
germinal centre where it undergoes SHM. N-gly sites are acquired early on in the process (purple 
figure), in the presumed precursor lesion, in situ follicular neoplasia (ISFN). As FL-like B cells are 
believed to represent the circulating counterparts of ISFN, N-gly sites may be retained in these cells 
also. Precursor cells which do not acquire sites through SHM undergo clonal deletion, assumed by the 
low frequency of site-negative subclones in the clonal repertoire. Clones maintain conservation of N-
gly sites during tumour evolution through ongoing SHM and gain of additional mutations, leading to 
an ancestral cell pool population, the CPC. With the exception of patient 5, the CPC provides a 
reservoir from which distinct disease events arise from, which retain the N-gly site.  At each stage of 
evolution, SHM results in the emergence of clones which lose N-gly sites due to the largely random 
nature of the process that does not distinguish between favourable and non-favourable mutations. 
However these represent only a minor mass of the heterogeneous tumour population and with the 
exception of patient 3, cannot traffic between events, indicating their insignificance in propagating 
progression and their likely loss from the clonal repertoire through cell death pathways. PFL - partial 













Figure 2. Early and late divergent evolution and N-gly acquirement. 
 




Figure 4. Lineage trees for patient 4 showing the N-gly site status of each subclone. 
 
Figure 5. Lineage trees for patient 5 showing the N-gly site status of each subclone. 
 




Figure 7. Simplified model of FL evolution and progression based on the high throughput sequencing of the 
immunoglobulin heavy chain variable gene and N-gly site analysis. 
 
 
 
